Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Each patient must meet all of the following inclusion criteria:~* Male patients 18 years or older~* Eastern Cooperative Oncology Group performance status 0-2~* Male patients who Practice effective barrier contraception during study and for 4 months after the last dose of study drug, OR Abstain from heterosexual intercourse.~* Voluntary written consent~* Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma without radiographic evidence of metastasis but with a rising PSA during or following the patient's most recent antineoplastic therapy despite castrate concentrations of testosterone~* Baseline PSA must be greater than or equal to 2 ng/mL and PSA doubling time must be less than or equal to 8 months OR baseline PSA must be greater than or equal to 8 ng/mL if PSA doubling time is greater than 8 months~* Has undergone orchiectomy or will continue receiving GnRH analogue therapy~* Meet screening laboratory values as specified in protocol~Exclusion Criteria:~Patients meeting any of the following exclusion criteria are not to be enrolled in the study:~* Known hypersensitivity to TAK-700 or related compounds~* Received any of the following within 30 days prior to the first dose of TAK-700: any investigational compound; prior herbal product known to decrease PSA; radiation therapy for prostate cancer; OR chronic therapy with corticosteroids~* Received prior therapy with aminoglutethimide or ketoconazole~* Received antiandrogen therapy within 4 weeks for flutamide and 6 weeks for all others prior to first dose of study drug~* Received prior chemotherapy for prostate cancer~* Current bladder neck outlet obstruction caused by prostate cancer, current spinal cord compression, or current bilateral hydronephrosis~* Symptoms that investigator deems related to prostate cancer~* Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected~* History of adrenal insufficiency~* Uncontrolled cardiovascular condition~* Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C~* Unwilling or unable to comply with protocol~* Major surgery or serious infection within 14 days of first dose of TAK-700~* Life-threatening illness unrelated to cancer~* Uncontrolled nausea, vomiting or diarrhea~* Known gastrointestinal disease or procedure that could interfere with oral absorption or tolerance of TAK-700

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAK-700 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).